Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Truist Financial Analyst Says

Revolution Medicines (NASDAQ:RVMD) had its price objective upped by Truist Financial from $231.00 to $239.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price target suggests a potential upside of 10.94% from the company’s current price.

RVMD has been the topic of a number of other research reports. Needham & Company LLC upped their target price on shares of Revolution Medicines from $236.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Sanford C. Bernstein boosted their target price on Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. Mizuho lifted their price objective on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a research note on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Finally, Piper Sandler boosted their price target on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.06.

Revolution Medicines Stock Up 1.9%

Shares of NASDAQ RVMD opened at $215.44 on Thursday. Revolution Medicines has a 1 year low of $35.64 and a 1 year high of $220.34. The company has a market capitalization of $46.18 billion, a P/E ratio of -24.43 and a beta of 1.39. The company has a 50 day simple moving average of $191.27 and a 200-day simple moving average of $147.30. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the prior year, the business earned ($1.31) earnings per share. On average, equities research analysts predict that Revolution Medicines will post -8.82 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Stephen Michael Kelsey sold 4,175 shares of Revolution Medicines stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total transaction of $651,801.00. Following the completion of the sale, the insider directly owned 291,876 shares of the company’s stock, valued at approximately $45,567,681.12. The trade was a 1.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark A. Goldsmith sold 80,000 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the transaction, the insider directly owned 267,330 shares in the company, valued at $55,925,436. This trade represents a 23.03% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 212,497 shares of company stock worth $38,206,486. Corporate insiders own 7.60% of the company’s stock.

Institutional Trading of Revolution Medicines

Institutional investors have recently modified their holdings of the stock. Meeder Advisory Services Inc. lifted its position in shares of Revolution Medicines by 3.0% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock valued at $401,000 after acquiring an additional 120 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Revolution Medicines by 1.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock worth $802,000 after buying an additional 125 shares in the last quarter. Deutsche Bank AG increased its holdings in Revolution Medicines by 0.4% during the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock valued at $2,566,000 after acquiring an additional 130 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Revolution Medicines by 147.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 218 shares of the company’s stock valued at $41,000 after purchasing an additional 130 shares in the last quarter. Finally, Contravisory Investment Management Inc. acquired a new stake in shares of Revolution Medicines in the second quarter valued at approximately $32,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approves RASONQUE: The FDA approved RASONQUE (daraxonrasib), Revolution Medicines’ oral RAS-targeted therapy, for adults with previously treated metastatic pancreatic ductal adenocarcinoma or patients unable to receive combination chemotherapy. The company describes it as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, creating a significant commercial opportunity in a disease with limited treatment options. FDA approval announcement
• Positive Sentiment: Commercial launch and pricing established: Revolution Medicines priced RASONQUE at approximately $39,800 per month, providing investors with an initial benchmark for potential sales and reimbursement economics. Rapid FDA approval also shortens the path from clinical development to revenue generation. RASONQUE pricing article
• Positive Sentiment: Analyst support increased: TD Cowen upgraded RVMD, adding to an already favorable analyst backdrop. Recent firms including Oppenheimer, Truist Financial, RBC and Needham have maintained Buy or Outperform ratings and raised price targets, reinforcing confidence in the drug’s launch and broader RAS-inhibitor pipeline. TD Cowen upgrade
• Neutral Sentiment: Stock already reflects substantial optimism: RVMD has risen sharply over the past year and is trading close to its $220.34 12-month high, with a market capitalization of about $46 billion. Investors may therefore demand strong launch execution and sales growth to justify the current valuation.
• Negative Sentiment: High price could weigh on adoption: The nearly $40,000 monthly list price has prompted concerns that payer negotiations, reimbursement hurdles or affordability issues could slow uptake, which may explain why investor enthusiasm has been more measured despite the approval. Drug pricing concerns
• Negative Sentiment: Insider selling: Director Mark Goldsmith sold 80,000 shares for approximately $16.7 million, reducing his holdings by about 23%. The sale does not change the company’s fundamentals but may create a modest sentiment overhang, particularly after the stock’s substantial advance. Insider sale report

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.